This is a story about the current activity in Chinese biopharma financing.
Chinese developers of cell and gene therapies continued to enjoy the limelight in July and August, although a summer lull set in for fundraisings backed by venture capital and private equity firms.
CorrectSequence Therapeutics, a clinical-stage developer of base-editing therapies, on 8 August announced the closing of a series A-plus round worth...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
